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The MLL1 gene is a frequent target for recurrent
chromosomal translocations, resulting in transfor-
mation of hematopoietic precursors into leukemia
stem cells. Here, we report on structure-function
studies that elucidate molecular events in MLL1
binding of histone H3K4me3/2 marks and recruit-
ment of the cyclophilin CyP33. CyP33 contains
a PPIase and a RRM domain and regulates MLL1
function through HDAC recruitment. We find that
the PPIase domain of CyP33 regulates the conforma-
tion of MLL1 through proline isomerization within the
PHD3-Bromo linker, thereby disrupting the PHD3-
Bromo interface and facilitating binding of the
MLL1-PHD3 domain to the CyP33-RRM domain.
H3K4me3/2 and CyP33-RRM target different sur-
faces of MLL1-PHD3 and can bind simultaneously
to form a ternary complex. Furthermore, the MLL1-
CyP33 interaction is required for repression of
HOXA9 and HOXC8 genes in vivo. Our results high-
light the role of PHD3-Bromo cassette as a regulatory
platform, orchestrating MLL1 binding of H3K4me3/2
marks and cyclophilin-mediated repression through
HDAC recruitment.INTRODUCTION
The mixed lineage leukemia 1 (MLL1) gene is essential for
embryonic development and hematopoiesis (Hess, 2004). The
encoded protein belongs to a family of H3K4 methyltransferases
(Milne et al., 2002; Nakamura et al., 2002), with a domain archi-
tecture that includes three AT-hook motifs, a transcriptional
repression region containing a CXXC zinc-finger domain, four
PHD fingers and one PHD-flanking bromodomain (Bromo),
FYRN and FYRC domains, and a C-terminal methyltransferase
SET domain (Figure 1A). The MLL1 gene is a frequent target
for chromosomal translocations in human acute myeloid
leukemia (AML) and acute lymphoblastic leukemia (ALL) (Aytonand Cleary, 2001). More than 70% of infant leukemias and
approximately 10% of adult AMLs involve MLL1 rearrange-
ments, which are often associated with a poor outcome. In
most MLL1 translocations, 1400 residues from the N terminus
of MLL1 are fused in-frame to one of more than 50 translocation
partners, a process that displaces the segment starting at the
PHD finger cluster and ending at the C-terminal SET domain.
Many MLL1 fusion partners belong to a protein network associ-
ated with transcriptional regulation through chromatin remodel-
ing, thereby implying that MLL1 fusions may correlate with
aberrant histone modifications at target promoters, such as
HOX gene clusters (Krivtsov and Armstrong, 2007; Linggi et al.,
2005).
MLL1 is a member of the trithorax group of proteins that func-
tion in opposition to the polycomb group proteins in maintaining
‘‘cellular memory’’ (Jenuwein and Allis, 2001). MLL1 is critical for
maintaining HOX gene expression during embryonic develop-
ment (Yu et al., 1995) and in hematopoiesis (Ernst et al., 2004).
MLL1 globally colocalizes with RNA polymerase II at the 50 end
of actively transcribed genes (Guenther et al., 2005; Milne
et al., 2005), which are also enrichment sites for histone H3 lysine
4 trimethylation (H3K4me3) marks (Guenther et al., 2005). This
coincidence of MLL1 target sites and H3K4me3 mark enrich-
ment at the genomic level implies that MLL1 recruitment to
such H3K4me3-enriched loci could be mediated in part by an
interaction involving one of its PHD fingers, a well-established
reader of methylated lysine marks (Ruthenburg et al., 2007a;
Baker et al., 2008).
MLL1 is a component of large nuclear complexes (Nakamura
et al., 2002; Dou et al., 2005) and is regulated through extensive
interactions with multiple proteins that either activate or sup-
press gene expression. Among suppressor factors, CyP33 is
quite unique in that it is neither a polycomb group protein nor
a histone deacetylase (HDAC). Rather, CyP33 is a cyclophilin
that contains an RNA recognition motif (RRM) within its
N terminus, separated by a long linker from its C-terminally posi-
tioned peptidyl prolyl isomerase (PPIase) domain. Moreover,
CyP33 is found in nuclear fractions of cultured cells exhibiting
overlapping patterns of nuclear localization with MLL1 (Mi
et al., 1996; Fair et al., 2001). CyP33 has been shown to specif-
ically interact with the third PHD finger (PHD3) of MLL1 (Fair
et al., 2001), and in the process facilitates an increase in the levelCell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc. 1183
Figure 1. Construct Design and Crystal Structure of MLL1 PHD3-Bromo Cassette in the Free State
(A) Domain architecture of MLL1 is shown in the top panel. Two coexpression constructs of MLL1 PHD3-Bromo cassette used for crystallization are shown in the
bottom panel.
(B) A ribbon view of the crystal structure of MLL1 PHD3-Bromo cassette with labeling of secondary structure elements. Pocket residues within PHD3 involved in
Kme recognition are shown in stick representation, together with residues involved in direct interaction at the interface of the PHD3-Bromo cassette.
(C) An expanded view highlighting the cis peptide bond at Pro1629 in the linker segment connecting MLL1 PHD3 and Bromo domains. Residues 1628–1630 are
shown in stick representation, with the corresponding 2Fo-Fc electron density contoured at 1s.
(D) An expanded view of the interdomain interaction between Glu1605 from PHD3 and the Val1723-Leu1724 backbone amides from Bromo.
(E) An expanded view highlighting the interfacial hydrophobic and hydrogen bonding interactions between PHD3 (in blue) and Bromo (in salmon).
(F) The partially formed Kme recognition pocket on the surface of PHD3. The Tyr1581 residue, which is not part of the aromatic-lined pocket, is indicated by a red
asterisk.
See also Figure S1.of HDAC1 binding to the MLL1 repression domain (Xia et al.,
2003). Both PPIase activity and RRM binding are required to
facilitate this switch in MLL1 function from transcriptional activa-
tion to repression (Fair et al., 2001; Xia et al., 2003). Despite these
advances, the molecular principles governing the interplay
between MLL1 and CyP33 remain elusive, given that there is
no understanding of the roles of the RRM and PPIase domains
of CyP33 in regulating the activity of MLL1. Further, since
MLL1 PHD3 is directly involved in binding CyP33 and is also pre-
dicted to be a potential reader of lysine methylation marks, it
remains unresolved as to how these two distinct molecular
events can be integrated together to provide comprehensive
mechanistic insights intoMLL1 function. To address these ques-
tions, we undertook systematic structure-function studies of the
MLL1 PHD3-Bromo cassette in the absence and presence of
bound histone peptides and CyP33.
In this study, we present X-ray and nuclear magnetic reso-
nance (NMR)-based structures of MLL1 PHD3-Bromo cassette
in the free state, as well in complexes with H3K4me3/2 peptides1184 Cell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc.and the RRM domain of CyP33. We also performed isothermal
titration calorimetry (ITC)-based binding and NMR-based titra-
tion studies to establish that the H3K4me3/2 marks and the
RRM domain target distinct surfaces of PHD3 and can coexist
as a ternary complex. Significantly, we demonstrate that
cis-trans isomerization of a linker proline within the MLL1
PHD3-Bromo cassette by the CyP33 PPIase domain dramati-
cally disrupts the interdomain contacts within the PHD3-Bromo
cassette, thereby topologically altering the relative alignments
of the PHD3 and Bromo domains and facilitating access of an
otherwise occluded PHD3 binding surface to the RRM domain.
Further, in vivo studies establish that CyP33 can be recruited
to the HOXA9 and HOXC8 genes independently of MLL1 but
that the MLL1-CyP33 interaction is required for histone deacety-
lase-mediated repression of these target genes in vivo. Collec-
tively, our studies establish a role for the MLL1 PHD3-Bromo
cassette as a functional platform connecting histone targeting
and CyP33-mediated regulation. These observations provide
insights into mechanisms that regulate MLL1 in its normal
physiological state and shed light on how MLL1 fusions are mis-
regulated as a result of dysfunction of this disease-associated
regulatory platform.
RESULTS
Crystal Structure of MLL1 PHD3-Bromo Cassette
in the Free State
To begin to understand the physical basis of chromatin interac-
tions of the PHD3-Bromo cassette of the MLL1 protein, we
sought to structurally characterize this region both alone and in
complex with relevant binding partners. Initially, we were unable
to express (in E. coli) and purify soluble constructs of the PHD3-
Bromo cassette, as a result of premature cleavage within the
ZA loop of Bromo. This problem was overcome by deletion of
residues 1666–1702 within the extra long ZA loop (Figure 1A
and Figure S1A available online) and coexpression of the result-
ing fragments in a duet vector. The coexpressed MLL1 PHD3-
Bromo cassette expressed well in E.coli and could be purified
to homogeneity.
The 1.72 A˚ crystal structure of the coexpressed MLL1 PHD3-
Bromo cassette (residues 1566–1784, with deletion of 1666–
1702 ZA loop segment) in the free state is shown in Figure 1B
(X-ray statistics in Table S1). Both PHD3 and Bromo adopt char-
acteristic folds of their family members. The linker segment
(1625–1631) connecting PHD3 and Bromo adopts a turn
segment, which leads into the extended a helix of Bromo. Signif-
icantly, Pro1629 in the linker segment adopts a cis conformation
(Figure 1C), facilitating an overall compact globular fold involving
the two domains, mediated in part by a pair of salt bridges
between a carboxylate group and backbone amide protons
(Figure 1D). The dominant interaction between PHD3 and Bromo
is mediated by the extended aZ helix of Bromo, which is
anchored in place by a network of hydrogen-bonding and hydro-
phobic interactions (Figure 1E; buried surface area 660 A˚2).
Residues Tyr1576, Met1585, and Trp1594 form a partial
aromatic cage on the surface of PHD3, with Tyr1581 positioned
nearby, but not part of, the cage in the free state (red asterisk in
Figure 1F).
Crystal Structure ofMLL1 PHD3-Bromo Cassette Bound
to H3(1-9)K4me3/2
By peptide pulldown assays, we first identified that the PHD3-
Bromo cassette is a reader of higher-order lysine methylation
states in the H3K4me context (Figure S1B). We then monitored
the binding energetics for complex formation between the coex-
pressed PHD3-Bromo cassette and H3(1-15)K4me-containing
peptides by ITC. PHD3 of the dual domain binds H3K4me3
and H3K4me2 peptides with dissociation constants (KD) of
4.3 mMand 6.9 mM, respectively, while it binds H3K4me1 peptide
with an approximately 10-fold weaker affinity (KD = 53 mM)
(Figure 2A). By comparison, MLL1 PHD3 alone showed much
weaker binding affinity for H3K4me-containing peptides as
measured by ITC (Table S2), which provided an early indication
that the adjacent Bromomay contribute to recognition of histone
methylation marks by MLL1 PHD3.
Bromodomains are well documented as acetyllysine-reading
modules (Zeng and Zhou, 2002; Mujtaba et al., 2007). The MLL1Bromo exhibits the typical bromodomain fold, with a main chain
root-mean-square deviation (rmsd) of 1.5 A˚ when compared to
BPTF Bromo (Li et al., 2006) (Figure S1C). To test whether
MLL1 Bromo also binds acetylated lysines, we expressed and
purified 15N-labeled MLL1 PHD3-Bromo cassette (1566–1784)
and MLL1 Bromo alone (1639–1784), without deleting the ZA
loop, using a modified expression protocol outlined in the
Extended Experimental Procedures. We did not observe any
complexation shifts in the 1H,15N-HSQC spectra of either the
PHD3-Bromo cassette or Bromo alone after addition of five
equivalents of H4(7-17)K12ac or H4(14-19)K16ac (Figure S1D)
peptides, as well as peptides containing H3K23ac and
H3K27ac modifications (data not shown). The inability of MLL1
Bromo to recognize acetyllysine in a range of histone sequence
contexts may be due to replacement of a conserved Asn in the
BC loop of acetyllysine-recognizing Bromos, such as Asn407 in
GCN5 (Owen et al., 2000) and Asn3007 in BPTF, by an Asp in
the corresponding position of MLL1 (Figure S1A).
Guided by the above binding studies, we next solved the
crystal structure of the coexpressed MLL1 PHD3-Bromo
cassette with bound H3(1-9)K4me3 peptide at 1.90 A˚ resolution
(Figure 2B; X-ray statistics in Table S1; electron density of bound
peptide shown in Figure S2A). The details of the molecular
recognition between residues 1 to 6 of H3K4me3 and MLL1
PHD3 in the complex are shown in Figure 2C, with the corre-
sponding stereo view shown in Figure S2B. The bound peptide
forms a b turn at the K4me3-Q5 step and is stabilized by a set
of intermolecular hydrogen bonds. The trimethylammonium
group of K4 is positioned within an aromatic cage composed
of Tyr1576, Tyr1581, Met1585, and Trp1594 side chains (Fig-
ure 2B), where it is stabilized by methyl-p and cation-p interac-
tions (Ma and Dougherty, 1997). The guanidinium group of R2 of
the bound peptide is directed away from the surface of PHD3,
and its 3 guanidinium proton is hydrogen bonded to the side
chain of Gln1587 (Figure 2C).
We also solved the 1.92 A˚ crystal structure of the complex of
the coexpressed MLL1 PHD3-Bromo cassette with H3(1-9)
K4me2 peptide (electron density of bound peptide shown in
Figure S2C; X-ray statistics in Table S1) and observed similar
intermolecular contacts as in the H3K4me3 complex (stereo
view in Figure S2D), with the ammonium proton of K4me2 form-
ing an intermolecular hydrogen bond with the peptide carbonyl
of Asp1580.
We mutated Tyr1581 and Trp1594 aromatic residues, which
line the aromatic pocket, to Ala and Glu, respectively, and also
mutated Gln1587, which forms a salt bridge with R2, to Ala so
as to measure the impact of these mutations on complex forma-
tion between H3K4me3/2 and PHD3-Bromo cassette by ITC. All
the abovemutants, which are associatedwith key intermolecular
contacts, are destabilizing and exhibit increased dissociation
constants (Table S2).
Conformational Changes in MLL1 PHD3 upon Complex
Formation
Quite unexpectedly, we observed that the aromatic ring of
Tyr1581 is looped out from the aromatic cage of PHD3 in
MLL1 PHD3-Bromo in the free state (Figure 1F) but flips inwards
by 3.1 A˚ to complete the aromatic cage upon formation of theCell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc. 1185
Figure 2. Crystal Structure of MLL1 PHD3-Bromo Cassette Bound to H3K4me3/2-Containing Peptides, Together with Binding Data onWild-
Type and Mutant PHD3
(A) ITC binding curves of MLL1 PHD3-Bromo cassette with H3K4me-containing peptides.
(B) A ribbon view of the crystal structure of MLL1 PHD3-Bromo cassette in complex with H3(1-9)K4me3 peptide. cis-configured Pro1629 and pocket residues for
trimethyl-lysine recognition are labeled accordingly.
(C) A view of the hydrogen bonding interactions between MLL1 PHD3 (blue) and bound H3K4me3 peptide (yellow) in the crystal structure of the complex.
(D) ITC profiles for the binding of H3(1-15)K4me3 peptide to wild-type (WT) MLL1 PHD3-Bromo and its W1594E, Y1581A, and Q1587A mutants.
(E) A view of the superimposed structures of the K4me3 binding pocket of MLL1 PHD3 in the free (silver) and H3K4me3-bound (blue) states. The blue and red
arrows highlight the conformational changes in the loop spanning Tyr1576-Met1585 segment and involving Tyr1581, respectively, on complex formation.
(F) A view of the superimposed structures of the peptide N terminus binding pocket of MLL1 PHD3 in the free (silver) and H3K4me3-bound (blue) states. The
Pro1614-Val1617 segment adopts an a helix (silver) in the free state but changes into a turn fold (blue) in the bound state.
(G) Surface electrostatic view of MLL1 PHD3 with bound H3(1-6)K4me3 peptide in a space-filling representation. Note that access is blocked to both the trime-
thylammonium group of H3K4me3 (indicated by red asterisk) and the N terminus (indicated by red pound symbol) in this complex.
(H) ITC profiles for the binding of MLL1 PHD3-Bromo to wild-type and two modified H3K4me3 peptides containing one or three additional Ala residues added to
the N terminus.
See also Figure S2.H3K4me3 complex (red arrow, Figure 2E). In addition to this
change, the loop segment between residues Tyr1576 and
Met1585 also undergoes a remarkable and previously unrecog-
nized conformational change by shifting (3.6 A˚) toward the
central b strands (b1 and b2) on complex formation (blue arrow,
Figure 2E), thus contributing to closing an additional face of the
aromatic cage. Strikingly, the conformational transition buries1186 Cell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc.the K4me3 side chain bound toMLL1PHD3 (Figure 2G), a feature
not observed previously for binding of the K4me3 side chain to
the preformed binding pocket of BPTF PHD2 (Li et al., 2006).
We also observed a conformational change within the
Asn1612-Ala1618 segment of PHD3 on formation of the
H3K4me3 complex (rmsd between states for this segment is
3.0 A˚). The Pro1614-Val1617 segment switches from an a-helical
Figure 3. MLL1 PHD3 Is Important for Stable Target Gene Binding In Vivo
(A) Positions of primer sets used for real-time PCR.
(B and C) ChIP analysis with antibodies for MLLC (B) or H3K4me3 (normalized to H3 levels) (C) at the target genes HOXA9, HOXC8, and p27KIP1. ChIP results
shown are typical for at least three independent experiments. Error bars represent standard deviation of three separate PCR reactions.
(D) Four separate stable cell lines were generated expressing the MLLN fragments fh-MLLCXXC-PHD3 and fh-MLLCXXC-PHD3 (W1594E) (W1594E point mutation in
MLL1 PHD3).
(E) ChIP signal with an HA antibody for the stable cell lines in (D) at MLL1 target genes. ChIP signal was calculated for each cell line individually, and then the
results for 2 and 3 were averaged together, as were the results for 4 and 5. Averages were the results of three independent experiments for each cell line. Error
bars represent standard deviation across the averaged values.conformer for the PHD3-Bromo cassette in the free state (ribbon,
silver color) to a turn fold on complex formation (stick, blue color)
as shown in Figure 2F. This transition tends to widen the channel
between segment 1612–1618 and the central b sheet, such that
A1 can be positioned snugly in the newly created pocket, with its
methyl group surrounded by a cluster of hydrophobic residues
on complex formation. The turn fold in the bound state of
PHD3 is stabilized by a set of direct and water-mediated inter-
molecular hydrogen bonds involving the N terminus of the bound
peptide (Figure 2F).
Concomitant with the conformational changes, the N terminus
of bound H3K4me3/2 becomes less accessible to solvent on
complex formation (Figure 2G). We designed experiments to
probe the accessibility of the N terminus of the bound
H3K4me3 peptide in the MLL1 PHD3-Bromo cassette complex
by measuring the impact on dissociation constants after addi-
tion of either a single Ala or an Ala-Ala-Ala tripeptide at the
N terminus. The dissociation constants increased by 6-fold on
addition of a single Ala (KD = 26 mM) and by 15-fold on addition
of an Ala-Ala-Ala tri-peptide (KD = 64 mM) (Figure 2H).
In all previously solved structures of H3K4me3/2-PHD finger
complexes, there were no evident conformational changes,
other than minor adjustments, in the K4me3 binding pocket on
the surface of the PHD finger (Taverna et al., 2007). In strikingcontrast to such static recognition pockets, the conformational
changes within H3K4me3/2-MLL1 PHD3 complexes involved
both significant side-chain and main-chain movements (Figures
2E and 2F), with such conformational transitions within recogni-
tion pockets also exhibiting qualitative differences between
recognition of H3K4me3 and H3K4me2 marks (stereo view in
Figure S2E). These conformational rearrangements contribute
to the binding specificity of MLL1 between methylation states
in the H3K4me context and also explain why a free N terminus
of the H3K4me-containing peptide is favored by the MLL1
PHD3 finger.
MLL1 PHD3 Is Important for Stable Target Gene Binding
In Vivo
To test the contribution of H3K4me3 binding to MLL1 function
in vivo, we examined the colocalization of MLL1 and H3K4me3
marks on well-established MLL1 target genes in vivo. Chromatin
immunoprecipitation (ChIP) assays were performed for four
regions on HOXA9 and HOXC8 loci and two regions on the
p27KIP1 locus (Figure 3A). Using an antibody against MLLC in
the ChIP assay, endogenous MLL1 binds to all the loci (Fig-
ure 3B) in a pattern that correlates reasonably well with the
relative level of H3K4me3 marks at these loci (Figure 3C).
To test the effect of H3K4me3-binding activity of MLL1, weCell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc. 1187
Figure 4. Complex Formation Results between Different Combina-
tions of Constructs of MLL1/2 PHD3-Bromo Cassette and CyP33
The # symbol indicates that complex was formed between PHD3-Bromo and
RRM by coexpression of vectors of PHD3-Bromo, RRM, and PPIase together
in E. coli. See also Figure S3.established four individual stable cell lines that express
FLAG and HA double-tagged MLLN fragments that were either
wild-type (fh-MLLCXXC-PHD3, lines 2 and 3) or mutant (fh-
MLLCXXC-PHD3 (W1594E), lines 4 and 5) for H3K4me3-binding
activity (Figure 3D). Lines 4 and 5 contain the W1594E mutation
in MLL1 PHD3 that specifically disrupts the binding between
MLL1 PHD3 and the H3K4me3 mark. Anti-FLAG western blots
indicate that expression levels were equal in all four cell lines
(Figure 3D). Using an anti-HA antibody, ChIP assays show that
the average combined signal for binding of the two mutant lines
(Figure 3E, green bars) is consistently 30% to 50% lower than the
two wild-type lines (Figure 3E, red bars), at primer positions B, C,
and D for HOXA9, C for HOXC8, and A for p27KIP1. These are all
primer positions in regions with relatively high levels of H3K4me3
(Figure 3C). For less abundant H3K4me3 regions, both frag-
ments showed low and comparable binding. These results veri-
fied that binding of H3K4me3marks byMLL1 PHD3 is important,
although not solely responsible, for MLL1 localization at target
genes (Milne et al., 2010).
PPIase-Mediated Complex Formation between MLL1
PHD3 and CyP33 RRM Domains
Cyclophilin CyP33, containing an independently folded N-ter-
minal RRM and a C-terminal PPIase, has been previously shown
to target MLL1 through recognition of PHD3 (Fair et al., 2001).
We tested for complex formation between intact CyP33 (1–301),
as well as its individual RRM (1–82) and PPIase (136–301)
domains, with either PHD3 alone or PHD3-Bromo cassette of
MLL1. We observed from gel filtration profiles that CyP33 RRM1188 Cell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc.formed a complex with the PHD3 domain alone (Figure 4, line 1,
and Figure S3A), but not with the PHD3-Bromo cassette
(Figure 4, line 3, and Figure S3B), and that complex formation
in the latter case occurred only in the context of full-length
CyP33 (Figure 4, line 4, and Figure S3C) or in the presence
of coexpressed CyP33 PPIase domain (Figure 4, line 5, and
Figure S3D). A more detailed analysis is outlined in the Extended
Experimental Procedures. Thus, the CyP33 PPIase domain
appears to regulate the interaction between CyP33 RRM and
MLL1 PHD3 in the presence of linked MLL1 Bromo, presumably
via its PPIase activity for peptidyl prolyl isomerization. Indeed,
the linker segment connecting PHD3 and Bromo of MLL1 con-
tains a single Pro at position 1629, with the His1628-Pro1629
peptide bond adopting a cis alignment both for PHD3-Bromo
in the free state (Figure 1C) and when bound to H3K4me3/2
peptides (Figure 2B). In this cisPro1629 conformation, a segment
of the surface of PHD3 is occluded through interaction with
Bromo (Figure 1E), suggesting that this buried surface in the
PHD3-Bromo cassette, were it to become accessible, could be
involved in interaction with the CyP33 RRM domain.
We next examined the impact of cis-trans conformational tran-
sition of Pro1629 and the requirement for CyP33 PPIase activity
in terms of the interaction between CyP33 and the MLL1 PHD3-
Bromo cassette. First, the CyP33 RRM domain interacted with
a PHD3-Bromo mutant, where Pro1629 was replaced by Ala,
so as to force a trans peptide bond at this position, even in
the absence of CyP33 PPIase domain (Figure 4, line 6, and
Figure S3E). Second, the double mutation F196E/M197E incor-
porated within the CyP33 PPIase domain, which disrupts the
hydrophobic propensity of the proline-binding pocket (Wang
et al., 2005), reduced the binding between CyP33 and PHD3-
Bromo (Figure 4, line 7, and Figure S3F). Taking these data
together, we infer that the CyP33 PPIase acts on the Pro1629
peptide bond to regulate, through cis-trans isomerization, the
interaction between CyP33 RRM and PHD3 in the context of
PHD3-Bromo cassette.
Intermolecular Interface between MLL1 PHD3
and CyP33 RRM on Complex Formation
We have solved the 2.0 A˚ crystal structure of the RRM domain of
CyP33 (5–82), whose topology is comprised of a four-stranded
antiparallel b sheet packed against two a helices (stereo view
in Figure S4A; X-ray statistics in Table S3). We next turned our
structural efforts to the NMR-based characterization of the
complex between MLL1 PHD3 and CyP33 RRM in solution.
We mapped NMR complexation shifts for amide resonances of
uniformly 13C,15N-labeled MLL1 PHD3 C1575S mutant upon
addition of unlabeled CyP33 RRM (Figure S4B), with the largest
complexation shifts (Ddave > 0.15 ppm, highlighted in yellow)
restricted to residues from the long a helix (a2) toward the
C-terminal end of the PHD3 domain (Figure 5A). In parallel, we
mapped complexation shifts for amide resonances of uniformly
13C,15N-labeled CyP33 RRM domain upon addition of unlabeled
MLL1 PHD3 C1575S mutant (Figure S4C), with the largest
complexation shifts (Ddave > 0.15 ppm, highlighted in yellow)
restricted to one face of the b sheet of the RRM domain, as
well as the loop connecting the second and third b strands (Fig-
ure 5B). Despite these insights, the NMR spectra of MLL1 PHD3
Figure 5. NMR-Based Mapping of Interacting Surfaces and Solution Structure Defining the Interface between MLL1 PHD3 and CyP33 RRM
(A) Crystal structure of MLL1 PHD3 (1566–1628) with labeling of secondary structure elements. Residues exhibiting large chemical shift perturbations (Ddave >




(B) Crystal structure of CyP33RRM (5–82) with labeling of secondary structure elements. Residues exhibiting large chemical shift perturbations (Ddave > 0.15 ppm)
upon interacting with unlabeled MLL1 PHD3 are colored in yellow.
(C) The backbone trace of 20 NMR refined structures of the complex containing the MLL1 PHD3 fragment (1603–1619, blue) and CyP33 RRM (2–82, magenta).
(D) An alternate view of the NMR solution structure of the complex between a fragment of MLL1 PHD3 (1603–1619, blue) and the CyP33 RRM (2–82, magenta).
(E) A ribbon representation of the interaction between MLL1 PHD3 fragment (1603–1619, blue) and CyP33 RRM (2–82, magenta) based on the NMR structure of
the complex. Residues involved in the interaction between MLL1 PHD3 and CyP33 RRM are colored in green and yellow, respectively.
(F) Spectral overlap of the selected regions of 1H,13C-HSQC of MLL1 (1566–1639; segment contains entire PHD3 finger, the linker, and a short segment of the aZ
helix of Bromo) in the free state (black) and bound to CyP33 RRM (1–82) (red).
(G) Model of the complex betweenMLL1 PHD3 (1566–1628, blue) and the CyP33 RRM (2–82, magenta) based on the structure in (D) after superimposing of their
respective PHD3 a2 helices.
(H) ITC curves for binding of H3(1-15)K4me3/2 peptide to the complex of MLL1 PHD3-Bromo and full-length CyP33.
(I) Complexation shifts in Trp1594 indole resonance (black cross peak) in the 1H,15N-HSQC spectrum of MLL1 PHD3 on sequential addition of H3K4me3 (green
cross peak), and CyP33 RRM (red cross peak).
See also Figure S4.bound to the RRM domain of CyP33 exhibited significant sig-
nal broadening and spectral overlap, precluding unambiguous
structural characterization of the complex.
To overcome the above limitations, and guided by the informa-
tion on interacting elements associated with complex formation
(Figures 5A and 5B), we next designed a construct in which the
interacting segment of MLL1 PHD3 (1585–1628) was fused to
the N terminus of CyP33 RRM (2–82) through a VD(GGS)4
peptide linker, so as to facilitate intramolecular complex forma-
tion. The 13C,15N-labeled fusion construct gave an exceptionally
well-resolved 1H,15N-HSQC NMR spectrum (Figure S4D), facili-tating resonance assignment and structure determination of
the complex. The defined segments of the complex are com-
posed of a fragment (1603–1619) of MLL1 PHD3 bound to intact
CyP33 RRM (20 superimposed structures shown in Figure 5C;
NMR statistics in Table S4). The long a helix a2 (1603–1611) of
MLL1 PHD3, along with its immediate downstream segment
(1612–1619), traverses along the exposed face of the b sheet
of the CyP33 RRM domain (Figures 5C and 5D), with this
association being primarily mediated by hydrophobic contacts
involving the side chains of Met1606, Ile1609, and Leu1610
along one face of the a helix of PHD3, projecting into the grooveCell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc. 1189
formed by Val7, Gln36, Phe51, Glu53, and Ala82 on the b sheet
face of RRM (Figure 5E). In addition, hydrophobic contacts
between Leu1613, Ala1618, and Tyr1619 residues C-terminal
to the a helix of PHD3 and Tyr9, Pro38, and Phe49 of RRM further
strengthen the association.
CyP33-Mediated cis-to-trans Transition of Linker
Pro1629 in MLL1 PHD3-Bromo Cassette
The structure of the complex (Figure 5D) confirms our deduction
that the surface of PHD3 that is buried because of its interaction
with Bromo within the PHD3-Bromo cassette is involved in the
interaction with CyP33 RRM. To expose this PHD3 surface for
targeting by the CyP33 RRM, a dramatic conformational change
has to occur, which necessitates repositioning of the PHD3 and
Bromo domains within the cassette. We anticipate that such
a transition requires Pro1629, located within the linker segment
connecting domains, to undergo a PPIase-mediated cis-to-trans
conformational transition. To directly monitor this transition, we
first characterized the configuration of Pro1629 in the MLL1
PHD3-Bromo cassette by NMR. The sequence specific chemi-
cal shift assignments of Pro1629-Ala1630 were achieved using
a uniformly 13C,15N-labeled sample, as well as a sample contain-
ing selectively 13C-labeled Pro and 15N-labeled Ala. The results
revealed that the His1628-Pro1629 peptide bond adopts a cis
configuration in theMLL1 PHD3-Bromo cassette in the free state
in solution, as reflected in the characteristic cis-Pro Cg chemical
shift of Pro1629 at 25.4 ppm (Figure S4E).
To facilitate monitoring the cis-to-trans transition of Pro1629
following MLL1 PHD3 binding to CyP33 RRM, we resorted to
a simpler system. We designed a short construct (residues
1566–1639) containing PHD3, Pro1629-containing linker, and
a part of helix aZ that is involved in the interaction with PHD3
(Figure 1E). The His1628-Pro1629 peptide bond predominantly
adopts a cis configuration in this construct in the free state, as
reflected in its major cross peak exhibiting a Cg chemical shift
of 25.3 ppm (Figure 5F, black cross peak P1629 cis). Upon
addition of CyP33 RRM, the Cg resonance of Pro1629 shifted
to 27.5 ppm (Figure 5F, red cross peak labeled P1629 trans),
a value characteristic of a trans Pro configuration. This estab-
lishes that the His1628-Pro1629 peptide bond in MLL1 PHD3-
Bromo transits from cis-to-trans configuration upon interaction
with CyP33 RRM.
MLL1 PHD3 Can Simultaneously Bind H3K4me3
and CyP33 RRM
We next aligned the crystal structure of full-length H3K4me3-
bound PHD3 (1566–1628) onto the NMR-based structure of
CyP33 RRM-bound MLL1 PHD3 fragment (1603–1619; Fig-
ure 5D), to yield a model of the H3K4me3-PHD3-RRM ternary
complex (Figure 5G). Notably, MLL1 PHD3 uses different
surfaces/pockets to bind H3K4me3 and the RRM domain of
CyP33. This was further confirmed from ITC-based binding
studies, where H3K4me3 and H3K4me2 peptides bound to the
complex of MLL1 PHD3-Bromo cassette and full-length CyP33
with KD values of 11.6 mM and 15.2 mM, respectively (Figure 5H).
These dissociation constants are increased by a factor of around
2 when compared to binary complex formation in the absence of
full-length CyP33 (Figure 2A).1190 Cell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc.Further, we used the well-resolved Trp1594 indole resonance
in the 1H,15N-HSQC spectrum of MLL1 PHD3 to monitor
complex formation on sequential addition of H3K4me3 and
CyP33 RRM. We observed a large downfield shift of the Trp
indole cross-peak on addition of H3K4me3 to form a binary
complex, followed by an upfield shift on addition of CyP33
RRM to form a ternary complex (Figure 5I). Similarly, addition
of the components in the reverse order resulted in the same shift
on ternary complex formation (Figure S4F). Together, these
results unequivocally confirm that MLL1 PHD3 uses different
surfaces to simultaneously bind H3K4me3 and CyP33 RRM.
Unique Features of MLL1 PHD3 among MLL Family
Members
Four members of the MLL SET family of histone methyl transfer-
ases, designated MLL1 to MLL4, contain one or more clusters of
PHD fingers (Ruthenburg et al., 2007a). We compared the
sequence of MLL1 PHD3 with other potential H3K4me-binding
PHD fingers from MLL SET family members. Sequence align-
ments show that the PHD3 domains of MLL1 and MLL2 (some-
times called MLL4 in the literature) exhibit the highest similarity
(70% identity) (Figure S3I). Unexpectedly, our gel filtration data
demonstrate that MLL2 PHD3 does not bind CyP33 RRM
(Figure 4, line 12, and Figure S3J). The loss of binding can be
attributed to replacement of CyP33 RRM-interacting residue
Met1606 on helix a2 of MLL1 PHD3 by corresponding residue
Asp1375 in MLL2 PHD3 (Figure S3I, residues labeled with green
background). In support of this inference, introduction of
a M1606D mutation into MLL1 PHD3 completely disrupted its
complex formation with CyP33 RRM (Figure 4, line 10, and
Figure S3K), thereby verifying the importance of hydrophobic
interactions at the interface of the PHD3-RRM complex (Fig-
ure 5E). Conversely, introduction of a D1375M mutation in
MLL2 PHD3 converted MLL2 PHD3 to a CyP33 RRM binding
partner (Figure 4, line 13, and Figure S3L). Similarly, the corre-
sponding residues in other potential H3K4me-binding PHD
fingers within MLL family members are either Asp or Glu
(Figure S3I), which indicates that regulation by CyP33 is specific
for MLL1 among MLL family members.
CyP33-Mediated Histone Deacetylation and Repression
of HOX Genes
To test whether the interaction between MLL1 and CyP33 was
necessary for target gene regulation in vivo, we made mutations
that disrupt the PPIase domain of CyP33 (F196E/M197E) (Wang
et al., 2005), as well as amutation in the RRM domain (F51D) that
should disrupt the MLL1-CyP33 interaction. In vitro, a single
mutation F51D in the RRMdomain that disrupts the hydrophobic
interaction between CyP33 RRM and MLL1 PHD3 was sufficient
to abolish the binding between CyP33 and MLL1 PHD3-Bromo
(Figure 4, line 11, and Figure S3M).
To test the impact of these mutants on CyP33-regulated HOX
gene expression, we transfected plasmids containing FLAG-HA-
tagged wild-type CyP33, CyP33 RRM mutant (F51D), or CyP33
PPIase-dead mutant (F196E/M197E) into 293T cells along with
an empty vector as the control. All three constructs expressed
well in 293T cells, and the expression levels were verified by
western blots with an anti-FLAG antibody (Figure 6A). In K562
Figure 6. Mutations in Either RRM or PPIase
Domains Affect CyP33-Regulated Gene Expres-
sion and Histone Deacetylation
(A) 293T cells were transiently transfected with an
empty vector (1, blue), wild-type full-length FLAG and
HA tagged CyP33 (2, red) or full-length CyP33 that has
either the F51D (3, green) or F196E/M197E (4, purple)
point mutations. A western blot with an anti-FLAG anti-
body indicates that all three constructs were expressed
at high levels.
(B) Real-time PCR quantification of gene expression levels
from the transfected cells in (A) shows that HOXA9 and
HOXC8 expression were reduced in the presence of
wild-type CyP33 (red bars) but not in cells expressing
the F51D (green bars)or F196E/M197E (purple bars) point
mutations or the empty vector control (blue bars). GAPDH
expression levels were unaffected by expression of any
constructs. Error bars represent the standard deviation
of two independent experiments.
(C and D) ChIP experiments with an anti-H3 pan acetyl
(AcH3) antibody (C), and an anti-HA antibody (D) at
HOXA9, HOXC8, and at a control region. PCR primer/
probe sets are as indicated in Figure 3. ChIP results shown are typical for at least three independent experiments. Error bars represent standard deviation of
three separate PCR reactions.
(C) ChIP shows decreased H3 acetylation levels atHOXA9 and HOXC8 in wild-type CyP33-expressing cells (red bars) but not in cells expressing the F51D (green
bars) and F196E/M197E (purple bars) point mutations or the empty vector control (blue bars).
(D) Anti-HA ChIP shows that wild-type (red bars) and F196E/M197E (purple bars) versions of CyP33 bound toHOXA9 and HOXC8, while the F51D point mutation
exhibited variably reduced CyP33 binding.
See also Figure S5.cells, CyP33 has been shown to be a repressor of the HOXC8
locus (Fair et al., 2001). Similarly, for 293T cells, we found that
overexpression of wild-type CyP33 resulted in an approximately
30%–40% downregulation of both HOXA9 and HOXC8 expres-
sion (Figure 6B), which is comparable to disruptions inHOX gene
expression that were seen with MLL1 complex component
knockdowns (Dou et al., 2006). As a comparison, overexpression
of the mutants F51D or F196E/M197E did not cause any repres-
sion of either HOX gene (Figure 6B).
Consistent with the gene-expression results, ChIP with an
anti-H3 pan acetyl antibody (AcH3) showed that HOXA9 and
HOXC8 loci exhibited decreased acetylation levels when wild-
type CyP33 but not its mutants were overexpressed (Figure 6C),
suggesting a role for histone deacetylation in repression (Xia
et al., 2003). In addition, CyP33 has no effect on MLL1 binding
at HOXA9 and HOXC8 (Figure S5), suggesting that its mecha-
nism of action does not involve modulating MLL1 binding to
target genes.
The CyP33 F51D mutant is only partially disrupted in its ability
to bind to HOXA9 and HOXC8 (Figure 6D). This suggests that
CyP33 recruitment to target genes in vivo is not dependent on
interacting with MLL1. However, since this mutant is unable to
deacetylate and repress target genes, this shows that the
CyP33 MLL1 interaction is essential for MLL1-mediated repres-
sion at these target genes. Thus, CyP33 is recruited to HOX
genes by a mechanism independent of MLL1 (perhaps through
other protein interactions or by interacting with a specific
RNA), but once it is bound to a target gene, its repressor function
requires a direct interaction with MLL1. These results establish
that the interaction between CyP33 and MLL1 is necessary
for CyP33-mediated histone deacetylation and repression of
HOXA9 and HOXC8 genes.DISCUSSION
Cis-trans Proline Isomerization within MLL1
PHD3-Bromo Controls Access to CyP33 RRM
Here, we present a detailed model of a PPIase-mediated
switch modulating the interaction between MLL1 PHD3-Bromo
and CyP33. PPIases belong to a ubiquitous protein family that
catalyzes the peptidyl prolyl cis-trans isomerization reaction
(Andreotti, 2003; Fangha¨nel and Fischer, 2004). PPIases play
an important role in protein folding/refolding by catalyzing
a rate-limiting step, as well as in protein transport and signaling
(Galat and Metcalfe, 1995). Our studies reveal that the inde-
pendently folded CyP33 RRM and PPIase domains, which
are separated by a long flexible linker without any hint of direct
interactions, have distinct and separable interaction surfaces
on the MLL1 PHD3-Bromo cassette. Based on our observa-
tions that CyP33 PPIase is required for the interaction between
CyP33 RRM and MLL1 PHD3-Bromo cassette but is not
associated with formation of a stable complex (Figure 4, line 5,
and Figure S3D), the main function of PPIase in this process
is as a chaperone that accelerates the cis-to-trans conforma-
tional transition of the His1628-Pro1629 peptide bond within
the linker segment. This transition in turn releases the other-
wise occluded surface of MLL1 PHD3, in the context of the
PHD3-Bromo cassette, for recognition by the RRM domain of
CyP33.
By comparison, an earlier functional study established proline
isomerization as a novel noncovalent histone modification that
regulates transcription by showing that the conformational state
of Pro38 on histone 3 is governed by the proline isomerase Fpr4,
which in turn controls methylation of H3K36 by Set2 (Nelson
et al., 2006). The above complementary examples at the readerCell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc. 1191
Figure 7. Schematic Outlining the Proposed Regulation of MLL1
Function by Cyclophilin-Mediated Proline Isomerization within
PHD3-Bromo Cassette
(A) A scheme showing transitions between two states of the MLL1 complex
mediated byCyP33. CyP33 binding toMLL1 increases the recruitment of core-
pressors to the repression domain, switching the balance of MLL1 functions
from activation to repression of target genes. It should be noted that involve-
ment of the RNA component in the scheme needs validation.
(B) Structure of MLL1 PHD3-Bromo cassette with cis-configured Pro1629 (left)
and model of MLL1 PHD3-Bromo-CyP33 RRM complex with trans-configured
Pro1629 (right).level (this study) and the histone peptide level (Nelson et al.,
2006) reinforce the concept that proline isomerization could
function on both sides of a regulatory switch controlling both
the relative topology of a single peptide or individual domains
and their downstream biological activities.
MLL1 PHD3-Bromo as a Regulatory PlatformControlling
Transcriptional Regulation
Previous biochemical studies, together with the molecular
details presented in this paper, enable us to generate a model
describing CyP33-mediated regulation of MLL1 (Figure 7A). In
the native state, MLL1 (as a complex of MLLN and MLLC) (Hsieh
et al., 2003) is targeted by corepressors and coactivators, while
exhibiting a net activation role in transcriptional regulation. MLL1
accumulates at H3K4me3-abundant regions of promoters
through PHD3-specific targeting, with the binding surface on
PHD3 for CyP33 RRM recognition blocked by Bromo because1192 Cell 141, 1183–1194, June 25, 2010 ª2010 Elsevier Inc.of a cis alignment at Pro1629 (Figure 7A, top segment). CyP33
binding catalyzes a cis-to-trans peptide bond conversion
at linker Pro1629, allowing MLL1 to transit to the CyP33
bound state, stabilized by interaction between the RRM domain
of CyP33 and its target site on PHD3, while retaining the ability
of MLL1 to bind nucleosomes through H3K4me3-based PHD3
recognition. As CyP33-mediated and/or HDAC1-related repres-
sion components accumulate at the MLL1 repression sites
(Xia et al., 2003), the overall functional balance of MLL1 switches
to repression (Figure 7A, bottom segment). AU-rich RNAs
may compete for binding to CyP33 RRM (Figure 7A, middle
segment) (Mi et al., 1996), thereby releasing CyP33 from the
MLL1 complex, resulting in MLL1 cycling back to the native
conformation.
In this model, H3K4me3/2 peptide and CyP33 RRM target
distinct surfaces on MLL1 PHD3 (Figure 5G) and thus can bind
simultaneously to form a ternary complex (Figures 5H and 5I).
The ability of a PHD finger to simultaneously bind histone
peptides and a range of interacting partners extends our under-
standing of PHD fingers, which function not only as readers of
histone marks, but also as mediators that interact with other
regulatory proteins. This concept is reinforced from a related
study of the Pygo1 PHD finger, which also uses two distinct
surfaces to simultaneously engage H3K4me3/2 peptide and
the HD1 domain of BCL9 (Fiedler et al., 2008). This property of
simultaneous binding also indicates that regulation of MLL1 by
CyP33 may also occur at the chromatin level, especially at
H3K4me3/2 enriched loci.
Our results also imply that after the recruitment of CyP33 to the
MLL1 PHD3-Bromo cassette, a large conformational rearrange-
ment between PHD3 and Bromo associated with the cis-trans
isomerization of the linker proline (Figure 7B) would result in
a dramatic reorientation of the remaining MLL1 domains relative
to each other, thereby potentially facilitating the recruitment of
other repression components.
Further, as the canonical RNA-binding surface of RRM (Cle´ry
et al., 2008) in CyP33 is involved in MLL1 PHD3 recognition
(Figure 5C) and CyP33 RRM has been shown to exhibit some
preference for AU-rich RNAs (Mi et al., 1996; Wang et al.,
2008), one anticipates competition between RNA and MLL1
PHD3 for binding toCyP33RRM, thereby providing amechanism
for releasing CyP33 from the MLL1 complex.
These results establish that the MLL1 PHD3-Bromo cassette
serves as a critical regulatory platform, connecting the down-
stream regulator CyP33 to the H3K4me3/2 enriched nucleo-
somal platform. Loss of this regulatory platform could contribute
to the leukemogenic potential of MLL1 fusion proteins. Support-
ing this concept, experiments with MLL1-ENL fusions have
shown that loss of the MLL1 PHD3 was necessary for MLL1-
ENL-induced immortalization of hematopoietic stem cells, while
insertion of MLL1 PHD3 into MLL1 suppressed such transforma-
tions (Chen et al., 2008). Similarly, insertion of the PHD3-contain-
ing region of MLL1 back into MLL1-AF9 fusions also blocked
immortalization of hematopoietic progenitors (Muntean et al.,
2008). An improved understanding of themolecular mechanisms
regulating interactions between MLL1 and CyP33 could provide
therapeutic insights into treatment of MLL1 aberrant-expression
related leukemias.
Concluding Remarks
Our structure-function studies have put forward the general
concept that the PHD3-Bromo cassette is key for both nucleo-
somal recruitment and CyP33 targeting of MLL1, adding new
insights into the potential function of multimodule reading
regions observed in many chromatin remodelers and histone-
modifying enzymes (Ruthenburg et al., 2007a). We envision
that linked multiple modules, such as the PHD3-Bromo cassette
of MLL1 studied here, are used not only to increase the binding
affinity and specificity of the writers and/or erasers that contain
them by engaging multiple marks in histone and/or DNA compo-
nents (Ruthenburg et al., 2007b), but also to modulate critical
associations with other components in themultisubunit architec-
ture that they reside in. Deletion of this region of MLL1 will not
only destabilize its recruitment to target promoter regions, but
also impair the CyP33 related repression pathway, disrupting
the balance between MLL1-mediated gene activation and
repression, thereby resulting in constant activation leading to
the onset of leukemogenesis.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Detailed methods for vector construction, GST-tagged or His-Sumo-tagged
protein expression and purification were outlined in the Extended Experi-
mental Procedures.
Crystallization and X-Ray Structure Determination
All the crystals were obtained by the hanging-drop method at 20C. Data sets
for crystals of MLL1 PHD3-Bromo cassette in the free form or in the complex
form with H3K4me3/2 peptides were collected at APS NE-CAT 24ID-C or
24ID-E beam lines. The free-form MLL1 PHD3-Bromo structure was solved
by SAD method with zinc anomalous signals. The subsequent complex struc-
tures of MLL1 PHD3-Bromo with H3K4me3/2 peptides were solved by molec-
ular replacement method using the free-form structure as the model. The data
set for CyP33 RRM crystals was collected on our in-house X-ray diffractom-
eter. The structure was solved by molecular replacement using the NMR
model of the structure in PDB (PDB ID: 2CQB). For detailed method of crystal-
lization and structure calculation, see the Extended Experimental Procedures.
NMR Sample Preparation and Structure Determination
Uniformly 15N,13C- or 15N-labeled proteins were expressed from Rosetta2
(DE3) E. coli cells in M9 minimum medium supplemented with 13C-labeled
glucose and/or 15N-labeled NH4Cl. For (U-
15N Ala, U-13C Pro)-selective
labeling, the medium was supplemented with 15N-labeled alanine and 13C-
labeled proline. The proteins were then subject to column purification before
NMR data collection. Sequence-specific chemical shift assignments were
achieved through a set of multidimensional heteronuclear NMR spectra. In
addition, NOE restraints for structural calculation were derived from a 3D
15N-edited NOESY-HSQC, a 3D aliphatic 13C-edited NOESY-HSQC, and
a 3D aromatic 13C-edited NOESY-HSQC. For details of structural calculation
and experimental procedures, see the Extended Experimental Procedures.
Isothermal Titration Calorimetry Measurements
Calorimetric experiments were conducted at 25C with a MicroCal iTC200
instrument. MLL1 PHD3-Bromo and its mutants purified by coexpression
method, or MLL1 PHD3 alone, were dialyzed overnight against buffer contain-
ing 20 mM Tris (pH 7.5), 100 mM NaCl, and 2 mM b-mercaptoethanol. The
sample of the MLL1 PHD3-Bromo-CyP33 complex was prepared by dialyzing
MLL1 PHD3-Bromo and CyP33 separately in above buffer first, then by mixing
together at 1:1.05 ratio for 2 hr on ice. Aliquots of lyophilized peptideswere dis-
solved in the same buffer before use. Calorimetric titration was performed by
injection of synthetic peptide into protein samples at various concentrations.Calorimetric titration data were fitted with software Origin 7.0 on the basis of
a 1:1 binding stoichiometry.
Peptide Pulldown Assays
All biotin-labeled histone peptides were synthesized by the Peptide Core
Facilities of Sloan-Kettering and Rockefeller University. Peptide pulldown
experiments were performed as described previously (Wysocka et al., 2006).
293T Transient Transfections
Constructs were transfected into 10 cm dishes of 293T cells with 1–2 mg of
DNA and 6 ml FuGene reagent according to the manufacturer’s instructions.
Forty-eight hours later, cells were collected and divided into two aliquots: (1)
whole-cell extracts were made with 300 mM KCl + 0.05% NP40 and used
for western blotting, and (2) RNA was purified with QIAGEN RNeasy kits and
complementary DNA (cDNA) was made with Invitrogen SuperScript II. cDNA
was then quantified in real-time PCR reactions with an ABI 7300 machine
and SYBR green with GAPDH-, HOXC8-, or HOXA9-specific primers.
293 Stable Cell Lines
293 cells were transfected with linearized vectors expressing either
fh-MLLCXXC-PHD3 or mutant fh-MLLCXXC-PHD3 (W1594E) under the control of a
CMV promoter and with an IRES/neo selection gene. Stably expressing cells
were selected for G418 resistance over a 1month period, and then expression
levels and ChIP experiments were done.
Chromatin Immunoprecipitation Experiments
ChIP experiments were performed as described previously (Milne et al., 2009).
Antibodies to H3K4me3 are from Active Motif (catalog# 39159), pan acetyl of
H3 from Upstate (catalog# 06-599), unmodified H3 from Abcam (catalog#
1791), and HA from Roche (clone 12CA5, catalog# 11583816001). Antibodies
to endogenous MLLC were a generous gift of the Robert Roeder laboratory.
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The X-ray coordinates of MLL1 PHD3-Bromo cassette in the free state (acces-
sion number 3LQH) and when bound to H3K4me3 (3LQJ) and H3K4me2 (3LQI)
peptides have been deposited in the Protein Data Bank (PDB). The X-ray coor-
dinates of CyP33 RRM domain in the free state (3LPY) and the NMR-based
coordinates for MLL1 PHD3-CyP33 RRM fusion protein (2KU7) have also
been deposited in the PDB. The NMR chemical shift assignments (16725)
have been deposited in Biological Magnetic Resonance Bank .
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